Pacira BioSciences senior vice president Lauren Riker sells $217,920 in stock
Pacira BioSciences (NASDAQ: PCRX) SVP Lauren Riker sold 6,000 shares for $217,920 at $36.32 each, under a 10b5-1 plan. She also acquired 6,000 shares via options. PCRX stock rose 44% in a week and 57% in a year. The company reported Q2 revenue of $192.4M, up 6%. Viatris acquired Pacira Pharmaceuticals for $1.65B, leading to mixed analyst reactions.
How this was made
The 30-second read
Why it matters
The insider transaction adds a micro‑level data point but is dwarfed by the larger acquisition news and earnings beat.
Market read
The article combines an insider filing with earnings beat and acquisition news, offering limited new trading impetus for PCRX.
What to watch
Recent revenue beat and analyst coverage upgrades may offset the negative perception of the insider sell.
Background
Pacira BioSciences reported a 6% Q2 revenue increase and received new analyst coverage, while Viatris announced an acquisition of Pacira Pharmaceuticals.
Ticker impact
Form 4 filing shows senior VP Lauren Riker sold 6,000 shares for $217,920 and bought 6,000 shares via options on Oct 8, 2026.
likely slight downward pressure as the market prices the insider sell
The transaction size is relatively small for a mid‑cap biotech and occurs alongside a buy, limiting directional impact.
Market effects
Minimal; the sale does not materially affect the broader biotech sector.
Limited to US investors tracking Pacira BioSciences.
Low; no global macro or sector ripple effects.
Counterpoint
The insider's simultaneous purchase could signal confidence, suggesting a potential upside despite the sell.
Key entities
- companyPacira BioSciences
Biopharmaceutical company reporting Q2 results and insider activity.
- companyViatris
Announced acquisition of Pacira Pharmaceuticals.
